Entera Bio Ltd logo

Entera Bio Ltd(ENTX)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
1-STAR RATING
Consider higher Upturn Star rating
BUY for 17 days
PROFIT SINCE LAST BUY
+5.77% ▲
LAST CLOSE
$3.3
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for ENTX

11/20/2026: ENTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Entera Bio Ltd is a clinical-stage biopharmaceutical company that develops oral tablet formulations of peptide and protein replacement therapies using its proprietary delivery platform. The company's primary strength lies in its innovative oral technology and lead candidate EB613 for osteoporosis, which offers a convenient alternative to traditional injections. Its main growth opportunity centers on expanding this platform into lucrative metabolic conditions like obesity alongside strategic industry partners. However, the company faces significant execution, regulatory, and financing risks given its pre-revenue status and high cash burn profile. The stock suits speculative growth investors willing to tolerate high volatility in exchange for potential clinical milestones.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitOffers high potential upside tied to clinical breakthroughs, but lacks commercial revenue growth today.
Momentum investorStrong fit while signal remains positiveTrades actively around clinical trial updates and biotech sector catalysts, making it attractive during positive momentum uptturns.
Value investorWeak fitLacks earnings, P/E ratios, and positive cash flows, rendering traditional value metrics inapplicable.
Dividend investorWeak fitDoes not pay dividends and retains all capital for clinical research.
Low-risk investorWeak fitHigh clinical, regulatory, and price volatility risks make it unsuitable for conservative portfolios.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighClinical-stage biotechnology stocks experience sharp price swings based on trial data and financing announcements.
Valuation riskHighWith negligible revenue, valuations rely entirely on speculative future commercial potential.
Competition risk (large pharmaceutical incumbents)HighWell-funded competitors can out-scale or out-market alternative therapies.
Business qualityMediumProprietary technology is robust, but commercial validation is unproven.
Dividend incomeLow / noneNo payouts are provided to investors.
Execution riskHighSuccess depends on complex clinical trials and regulatory approvals.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 571.17M USD
Price to earnings Ratio -
1Y Target Price 9.75
Price to earnings Ratio -
1Y Target Price 9.75
Volume (30-day avg) 401.9K shares
Beta 1.46
52 Weeks Range 0.91 - 4.20
Updated Date 11/20/2026
52 Weeks Range 0.91 - 4.20
Updated Date 11/20/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.4

Sector & Industry Intelligence

Sector

Healthcare

Constructive
Sentiment
Strong Bullish
Momentum
BUY Breadth Improving
BUY participation
55.2%
Active BUY / eligible
53 / 96
30-Day BUY Count Change
+19
Market state
Strong Bullish

More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.

Industry

Biotechnology

BUY participation
43.2%
Active BUY / eligible
19 / 44
30-Day BUY Count Change
+12

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit 38.86%
Avg. Invested days 23
Today’s Advisory Consider higher Upturn Star rating
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 3.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
ENTX receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics.

Company Fundamentals

★★★★★
ENTX has moderate overall fundamentals (3 stars), with soft financial health, soft growth momentum, and solid ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-19.9%), weak cash generation (FCF margin -17802.4%), negative revenue growth (-76.8%).

Financial Health Rating

★★★★★
ENTX's financial health is soft, with the relatively strongest area being moderate liquidity, including working-capital and asset support (WC/assets 81.9%). Operating efficiency is weak (1 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
ENTX's growth profile is soft, with the least-weak measure being free-cash-flow growth at -9.6% FY2025 versus FY2024. By comparison, while revenue growth (-76.8%, negative) and earnings growth (-19.9%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 80.4% and approximately 61.6% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 5.42% supports management-shareholder alignment.

Top 5 Institutional Investors

Knoll Capital Management LP 3.38%
Bvf Inc 1.39%
Siren, L.L.C. 0.42%
Parkman Healthcare Partners LLC 0.16%
PNC Financial Services Group Inc 0.16%

Unit Economics (Per $1K Revenue)

★★★★★
ENTX generates approximately $-714 of gross profit, $-274,500 of operating income, and $-178,024 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -100.79% (Tax Credit)

Quantitative Style Profile

★★★★★
ENTX has a liquid profile. Elevated volatility is the primary drawback.

Style Classification

Quality Focused

High VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Research Collaborations & GrantsEarly-stage development fees, research services, and grant funding from partnership agreements.The company generates minimal revenue currently, functioning entirely as a pre-commercial research enterprise.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 303.94M
Price to Sales(TTM) -
Enterprise Value 303.94M
Price to Sales(TTM) -
Enterprise Value to Revenue 452.96
Enterprise Value to EBITDA -1.52
Shares Outstanding 174.14M
Shares Floating 107.29M
Shares Outstanding 174.14M
Shares Floating 107.29M
Percent Insiders 5.42
Percent Institutions 80.38

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.